Alleviation of non-alcoholic fatty liver disease by Huazhi Fugan Granules is associated with suppression of TLR4/NF-κB signaling pathway
- PMID: 33810882
- DOI: 10.1016/j.arteri.2020.12.007
Alleviation of non-alcoholic fatty liver disease by Huazhi Fugan Granules is associated with suppression of TLR4/NF-κB signaling pathway
Abstract
Introduction: In parallel with the improvement of living standard, Non-alcoholic fatty liver disease (NAFLD) becomes the most common liver disease around the world. Huazhi Fugan Granules (HZFGG) is a formula which is used to treating of fatty liver, Based on the data we studied, HZFGG may have potential as a therapeutic formula for the alleviation of NAFLD.
Objectives: The aim of our study was to identifying the improvement of HZFGG on NAFLD and exploring the potential mechanisms.
Methods: MCD diet fed C57BL/6 mice once a day for 4 weeks to induce NAFLD model, HZFGG (10, 15, 20g/kg) orally administered simultaneously. The serum levels of TC, TG, ALT, AST were detected. H&E and Oil Red O staining were used to observed the liver sections. TNF-α, IL-1β and Gpx were also detected. The expression levels of TLR4, MyD88, p-NF-κB, NF-κB, p-IκBa were measured by western blotting assay. The apoptosis of the liver tissues were detected by TUNEL assay.
Results: HZFGG decreased the serum levels of TC, TG, ALT, AST in MCD-diet mice. HZFGG alleviated inflammation by decreasing the levels of TNF-α and IL-1β and ameliorated oxidative stress through increased the level of Gpx. HZFGG Attenuates MCD-induced liver steatosis and injury in mice. Hepatocyte apoptosis was decreased after HZFGG treatment. Furthermore, HZFGG also suppressed the expression levels of TLR4 and MyD88, subsequently, inhibited the phosphorylation of NF-κB and IκBa.
Conclusion: HZFGG can improved MCD induced hepatic injury through inhibited TLR4/NF-κB signaling pathway in NAFLD model.
Keywords: Enfermedad de hígado graso no alcohólico; Gránulos de Huazhi Fugan; Huazhi Fugan Granules; NF-kappa B; NF-κB; Nonalcoholic fatty liver disease; Receptor-4 «toll-like»; Toll-like receptor-4.
Copyright © 2021 Sociedad Española de Arteriosclerosis. Publicado por Elsevier España, S.L.U. All rights reserved.
Similar articles
-
Role of targeting TLR4 signaling axis in liver-related diseases.Pathol Res Pract. 2023 Apr;244:154410. doi: 10.1016/j.prp.2023.154410. Epub 2023 Mar 7. Pathol Res Pract. 2023. PMID: 36917917 Review.
-
Regulatory Networks, Management Approaches, and Emerging Treatments of Nonalcoholic Fatty Liver Disease.Can J Gastroenterol Hepatol. 2022 Nov 8;2022:6799414. doi: 10.1155/2022/6799414. eCollection 2022. Can J Gastroenterol Hepatol. 2022. PMID: 36397950 Free PMC article. Review.
-
Berberine inhibits liver damage in rats with non-alcoholic fatty liver disease by regulating TLR4/MyD88/NF-κB pathway.Turk J Gastroenterol. 2020 Dec;31(12):902-909. doi: 10.5152/tjg.2020.19568. Turk J Gastroenterol. 2020. PMID: 33626003 Free PMC article.
-
BabaoDan cures hepatic encephalopathy by decreasing ammonia levels and alleviating inflammation in rats.J Ethnopharmacol. 2020 Mar 1;249:112301. doi: 10.1016/j.jep.2019.112301. Epub 2019 Oct 14. J Ethnopharmacol. 2020. PMID: 31622746
-
A study of regulatory effects of TLR4 and NF-κB on primary biliary cholangitis.Eur Rev Med Pharmacol Sci. 2019 May;23(9):3951-3959. doi: 10.26355/eurrev_201905_17824. Eur Rev Med Pharmacol Sci. 2019. PMID: 31115023
Cited by
-
Esculeogenin A, a Glycan from Tomato, Alleviates Nonalcoholic Fatty Liver Disease in Rats through Hypolipidemic, Antioxidant, and Anti-Inflammatory Effects.Nutrients. 2023 Nov 11;15(22):4755. doi: 10.3390/nu15224755. Nutrients. 2023. PMID: 38004149 Free PMC article.
-
Potential hepatoprotective effects of Cistanche deserticola Y.C. Ma: Integrated phytochemical analysis using UPLC-Q-TOF-MS/MS, target network analysis, and experimental assessment.Front Pharmacol. 2022 Oct 12;13:1018572. doi: 10.3389/fphar.2022.1018572. eCollection 2022. Front Pharmacol. 2022. PMID: 36313288 Free PMC article.
-
PCSK9 Promotes Endothelial Dysfunction During Sepsis Via the TLR4/MyD88/NF-κB and NLRP3 Pathways.Inflammation. 2023 Feb;46(1):115-128. doi: 10.1007/s10753-022-01715-z. Epub 2022 Aug 5. Inflammation. 2023. PMID: 35930089
-
Update on Pharmacological Activities, Security, and Pharmacokinetics of Rhein.Evid Based Complement Alternat Med. 2021 Aug 17;2021:4582412. doi: 10.1155/2021/4582412. eCollection 2021. Evid Based Complement Alternat Med. 2021. PMID: 34457021 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous